Biopharma and healthcare group Chiesi Farmaceutici S.p.A. is to acquire the 2015-established Amryt Pharma Plc. in an all-cash transaction at $14.50 per American Depositary Share (ADS). Each ADS ...

UK-based specialist Amryt Pharma is looking to expand in 2018 after acquiring two rare disease treatments. A relative newcomer to the niche rare disease market, Amryt Pharma was founded by former ...

Amryt is a global commercial-stage biopharmaceutical company focused on acquiring, developing and commercializing innovative treatments to help improve the lives of patients with rare and orphan ...